CJ 12406

Drug Profile

CJ 12406

Alternative Names: CJ-12406

Latest Information Update: 09 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CJ Cheiljedang Corp.
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 07 May 2013 Phase-I development is ongoing in South Korea
  • 30 Jun 2012 CJ Cheiljedang Corp. completes a phase I trial in healthy volunteers in South Korea (NCT01489774)
  • 11 Dec 2011 Phase-I clinical trials in Gastro-oesophageal reflux in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top